Monitoring dyskinesia with Zif.
Fisone
Gilberto
G
Department of Neuroscience, Karolinska Institutet, Retzius väg 8, 171 77 Stockholm, Sweden. gilberto.fisone@ki.se
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D015415:Biomarkers; D004298:Dopamine / Q000502:physiology; D018491:Dopamine Agonists / Q000494:pharmacology; D004409:Dyskinesia, Drug-Induced / Q000235:genetics / Q000503:physiopathology*; D051766:Early Growth Response Protein 1 / Q000096:biosynthesis / Q000235:genetics* / Q000502:physiology; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D010300:Parkinson Disease / Q000150:complications; D011954:Receptors, Dopamine / Q000235:genetics
D000978:Antiparkinson Agents; D015415:Biomarkers; D018491:Dopamine Agonists; C497325:EGR1 protein, human; D051766:Early Growth Response Protein 1; D007211:Indoles; D011954:Receptors, Dopamine; C046649:ropinirole; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D004298:Dopamine